rs3761847 — TRAF1

TRAF1-C5 — The Inflammatory Signal Amplifier at Chromosome 9q33

Deep within the long arm of chromosome 9 sits a genetic locus that helps explain why rheumatoid arthritis clusters in families and why some patients respond poorly to the most effective treatments available. The TRAF1-C5 locus¹¹ The TRAF1-C5 locus
TRAF1 encodes TNF receptor-associated factor 1, a scaffold protein inside immune cells that amplifies inflammatory NF-kB signaling; C5 encodes complement component 5, a protein that drives joint inflammation through the complement cascade at 9q33.3 contains two genes, each contributing to the inflammatory cascade that erodes joints in autoimmune arthritis. rs3761847 is an intronic variant in TRAF1 that serves as the principal GWAS tag SNP for this entire locus — its G allele marks a chromosomal haplotype that increases susceptibility to rheumatoid arthritis by approximately 32% per copy.

The Mechanism

rs3761847 sits in an intron of TRAF1 on chromosome 9 (GRCh38 position 120,927,961), with the TRAF1 gene encoded on the minus strand. The variant itself is not a coding change — it does not alter any amino acid. Instead, it acts as a linkage disequilibrium tag²² linkage disequilibrium tag
A tag SNP marks a haplotype block: it travels with nearby functional variants through generations because recombination between them is rare, making the tag SNP a reliable proxy for the causal variant(s) for a haplotype that alters TRAF1 expression in immune cells.

TRAF1 protein is a key intracellular scaffold in the TNF receptor signaling pathway. When TNF-alpha binds its receptor on immune cells, TRAF1 is recruited to the receptor complex and modulates the downstream activation of NF-kB³³ NF-kB
Nuclear factor kappa-light-chain-enhancer of activated B cells — a master transcription factor that switches on hundreds of pro-inflammatory genes including cytokines, chemokines, and adhesion molecules that drive joint inflammation. Higher TRAF1 expression — associated with the G-allele haplotype — amplifies NF-kB activation in CD14+ monocytes and other inflammatory cells, tilting the immune response toward persistent inflammation rather than resolution. Studies in Japanese RA patients found significantly elevated TRAF1 protein in monocytes from G-allele carriers, providing a direct mechanistic link between genotype and cellular phenotype.

The neighboring C5 gene contributes through a separate mechanism: complement component 5 is cleaved to C5a in the synovial fluid of inflamed joints, where it drives macrophage activation and inflammatory cytokine release. The G-allele haplotype at rs3761847 spans both genes, potentially influencing both TRAF1-mediated NF-kB amplification and complement-driven synovial inflammation.

The Evidence

The foundational discovery came from Plenge et al. (2007)⁴⁴ Plenge et al. (2007)
NEJM genome-wide study analyzing 317,503 SNPs in 1,522 anti-CCP-positive RA cases and 1,850 controls from NARAC and EIRA cohorts, replicated in an additional 997 cases and 1,777 controls, who identified rs3761847 as the top signal at the TRAF1-C5 locus with an odds ratio of 1.32 (95% CI 1.23–1.42, p = 4×10⁻¹⁴) in anti-CCP-positive rheumatoid arthritis — one of the most significant non-HLA genetic associations for RA at that time. Crucially, the effect was strongest in seropositive (anti-CCP-positive) disease, which is the most genetically driven, erosive form of RA.

A meta-analysis by Song et al. (2014)⁵⁵ meta-analysis by Song et al. (2014)
Immunological Investigations meta-analysis encompassing 24 studies with 22,682 RA cases and 23,493 controls across European and Asian populations confirmed the European association (OR 1.156, 95% CI 1.006–1.327 per G allele) while finding no statistically significant effect in Asian cohorts (OR 1.049, p = 0.333). This ethnic divergence is explained by differences in linkage disequilibrium⁶⁶ linkage disequilibrium
LD refers to the non-random co-inheritance of alleles; if the causal variant is in strong LD with rs3761847 in Europeans (r²=0.67) but weaker LD in Asians (r²=0.37), the tag SNP is more informative in the former between rs3761847 and the actual functional variant(s) in the two population groups.

Replication in East Asian populations confirmed the locus itself matters: Zhu et al. (2011)⁷⁷ Zhu et al. (2011)
BMC Medical Genetics, 576 RA patients and 689 controls in Han Chinese found significant association of rs3761847 (p = 0.0018, OR 1.28) in their Han Chinese cohort, independent of anti-CCP and RF concentrations — demonstrating that the genetic effect at this locus is not simply a proxy for serological status.

Beyond susceptibility, the TRAF1-C5 locus influences treatment outcomes. Canhão et al. (2015)⁸⁸ Canhão et al. (2015)
Biomedical Research International, Southern European RA patients on anti-TNF therapy found that the G risk allele at rs3761847 predicted poor response to anti-TNF biologics in multivariate analyses. This is mechanistically coherent: if the G haplotype drives higher TRAF1 expression and stronger NF-kB activation, those same pathways may counteract TNF blockade.

Practical Actions

For G-allele carriers — particularly GG homozygotes — the key clinical implications are threefold: early awareness of seropositive RA symptoms, proactive monitoring of relevant biomarkers (anti-CCP antibodies and CRP), and awareness that standard anti-TNF biologic therapy may be less effective for GG carriers. These individuals may benefit from JAK inhibitors or IL-6 pathway inhibitors as preferential first-line biologic options when conventional DMARDs fail, since these targets operate downstream of or parallel to TRAF1-mediated NF-kB signaling.

The G allele is approximately 43% globally and 42% in Europeans, making it common rather than rare. Most Europeans carry at least one copy. GG homozygotes (~18% in Europeans) carry the highest genetic burden at this locus. Seronegative RA patients should note that the evidence for this locus is substantially weaker outside the anti-CCP-positive disease subtype.

Interactions

rs3761847 sits in a pathway heavily influenced by other autoimmune susceptibility loci. The TNFAIP3 locus on chromosome 6q23 — specifically rs6920220 and rs13207033 — encodes A20, the primary brake on NF-kB signaling that TRAF1 activates. Carriers of both a TRAF1-C5 G risk allele and TNFAIP3 risk variants face a double hit: amplified NF-kB signaling (via TRAF1) combined with impaired NF-kB termination (via A20 deficiency). The PTPN22 rs2476601 variant (R620W) represents a third independent RA risk signal that alters T-cell receptor signaling thresholds, and its combination with TRAF1-C5 G-allele carriage further elevates seropositive RA risk.